Overview
development of reagents for protein and peptide radioiodination that decrease deiodination in vivo by up to 100-fold, b) demonstration that At-211 labeled monoclonal antibodies are effective in the treatment of a rat model of neoplastic meningitis, c) synthesis of a thymidine analogue labeled with At-211 and the demonstration that this molecule is taken up in cellular DNA with highly cytotoxicity even at levels of only one atom bound per cell and d) development of
radiohalobenzylguanidines which are specifically cytotoxic for human neuroblastoma cells.
Current Appointments & Affiliations
Jonathan Spicehandler, M.D. Distinguished Professor of Neuro Oncology, in the School of Medicine
·
2008 - Present
Radiology,
Clinical Science Departments
Professor of Radiology
·
2018 - Present
Radiology,
Clinical Science Departments
Professor of Radiation Oncology
·
2009 - Present
Radiation Oncology,
Clinical Science Departments
Professor in Pathology
·
2017 - Present
Pathology,
Clinical Science Departments
Professor of Biomedical Engineering
·
2024 - Present
Biomedical Engineering,
Pratt School of Engineering
Member of the Duke Cancer Institute
·
1985 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Enhancing the therapeutic index of [211At]YF2 with iodo pseudo carrier: A simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands.
Journal Article Nucl Med Biol · May 11, 2025 INTRODUCTION: Low-molecular-weight (LMW) PSMA-targeted agents have enjoyed success; however, their off-target toxicity in normal tissues such as kidneys, salivary gland and lacrimal gland can be dose limiting. Herein, we have evaluated the effect of co-adm ... Full text Link to item CiteA third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation.
Journal Article Nucl Med Biol · 2024 INTRODUCTION: Targeted α-particle therapy agents have shown promising responses in patients who have developed resistance to β--particle emitting radionuclides, albeit off-target toxicity remains a concern. Astatine-211 emits only one α-particle per decay ... Full text Link to item CitePSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
Journal Article Nucl Med Biol · 2024 INTRODUCTION: Single domain antibody fragments (sdAbs) are an appealing scaffold for radiopharmaceutical development due to their small size (~15 kDa), high solubility, high stability, and excellent tumor penetration. Previously, we developed NB7 sdAb, whi ... Full text Link to item CiteRecent Grants
Small Molecule PSMA-Targeted Alpha Therapy
ResearchPrincipal Investigator · Awarded by University of Texas Southwestern Medical Center · 2024 - 2026Targeting neuroendocrine cells in prostate cancer with small molecule and targeted radionuclide therapies
ResearchCo Investigator · Awarded by Prostate Cancer Foundation · 2023 - 2025PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2025View All Grants
Education, Training & Certifications
Washington University in St. Louis ·
1974
Ph.D.
Washington University in St. Louis ·
1972
M.A.